Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?

Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KİRAZLI Ş., ...More

ANNALS OF ONCOLOGY, vol.15, no.11, pp.1622-1626, 2004 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 15 Issue: 11
  • Publication Date: 2004
  • Doi Number: 10.1093/annonc/mdh437
  • Journal Name: ANNALS OF ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1622-1626
  • Keywords: breast cancer, hemostasis, hypercoagulability, tamoxifen, TFPI, venous thromboembolism, ACTIVATED PROTEIN-C, SYSTEMIC-LUPUS-ERYTHEMATOSUS, COMBINED ORAL-CONTRACEPTIVES, HORMONE REPLACEMENT THERAPY, FACTOR-V-LEIDEN, BREAST-CANCER, ADJUVANT THERAPY, VENOUS THROMBOSIS, ANTITHROMBIN-III, BLOOD-COAGULATION
  • Hacettepe University Affiliated: Yes

Abstract

Background: Current understanding of hemostatic systems enables us to better explore the enigmatic pathobiology of tamoxifen (TAM)-induced thrombotic diathesis. We have therefore aimed to assess the hemostatic changes in breast cancer patients receiving TAM on an adjuvant basis.